| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447879 | European Journal of Cancer | 2010 | 8 Pages |
Abstract
The results of the present study show that the addition of topotecan to a standard paclitaxel/carboplatin regimen in the treatment of advanced epithelial ovarian cancer did not result in significant advantages in terms of survival rate. A slightly worse toxicity profile for TPC was observed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Giorgio Bolis, Giovanna Scarfone, Francesco Raspagliesi, Giorgia Mangili, Saverio Danese, Paolo Scollo, Domenica Lo Russo, Antonella Villa, Paola Daniela Aimone, Giovanni Scambia,